The cutting-edge research, led by Nobel laureate David Baker and the Institute for Protein Design at UW Medicine, utilizes AI tools to engineer proteins that can recognize unique peptides on cell surfaces. These custom-designed proteins are then integrated into chimeric antigen receptors (CARs) to activate T cells and attack specific targets, such as cancerous cells or virus-infected cells.
In a recent study published in Science, researchers successfully designed proteins for 11 peptide targets, with eight of them triggering a T-cell response. Notably, two of these proteins induced a strong immune response that led to the targeted cell’s destruction. The targets included fragments of HIV and mutations in tumor-related proteins.
This breakthrough in protein design could revolutionize precision immunotherapy, paving the way for personalized treatment strategies tailored to individual patients’ needs. By leveraging AI technology, the research team was able to rapidly adapt their protein designs to target new cancer and virus-associated peptides, making personalized therapies more accessible and cost-effective.
The potential impact of this research extends beyond cancer treatment, with implications for developing pharmaceuticals, vaccines, nanomaterials, and sensors. The open-source software used in the study is available online for researchers worldwide to access and further advance this groundbreaking technology.
Co-lead author Bingxu Liu, a postdoctoral scholar at the Baker Lab, expressed optimism about the future of personalized cancer therapy, emphasizing the team’s commitment to translating their research into tangible benefits for patients. With a track record of spinning off startups and commercializing innovative technologies, the Institute for Protein Design is poised to bring this cutting-edge therapy to market and make a lasting impact on global healthcare.
